Abstract
Electrospun nanofiber‐mediated drug‐delivery systems are extensively applied for the controlled delivery of anticancer agents and localized cancer chemotherapy. In this work, we assessed the synergistic anticancer effect of polyurethane‐polycaprolactone (PU‐PCL) nanofibers (NFs) on prostate cancer cell line (PC3) and evaluate their antitumor activity in vitro. Polyurethane‐polycaprolactone (PU‐PCL) nanofibers were prepared by electrospinning and used for codelivery of doxorubicin hydrochloride (DOX) and ezetimibe (EZ). The morphology, weight loss, and swelling ability of the PU‐PCL nanofibers were characterized. Drug release test was performed by UV‐vis spectroscopy in a phosphate buffer at pH 7.4 at 37°C. The viability of the PC3 prostate cancer cells was evaluated by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay for the different periods of cell incubation. PC3 prostate cancer cells were treated with different concentrations of 0‐50 μg/ml of DOX, EZ, DOX‐loaded NFs, EZ‐loaded NFs, and DOX‐EZ coloaded NFs for 48 hours. The results demonstrated that electrospun PU‐PCL NFs showed significant synergistic therapeutic efficacy on prostate cancer cells. This study proposes that the DOX‐EZ codelivery using PU‐PCL nanofibrous scaffold could be used as a possible approach for anticancer drug delivery for the treatment of prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
